Abstracts tagged "Infection"

Abstract Number: 0349 • ACR Convergence 2022
Comparative Risks of Infection with Belimumab versus Oral Immunosuppressants in Patients with Non-Renal Systemic Lupus Erythematosus
Emma Materne¹, Hyon Choi², Baijun Zhou¹, Karen Costenbader³, Yuqing Zhang⁴ and April Jorge¹, ¹Massachusetts General Hospital, Boston, MA, ²MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Massachusetts General Hospital, Quincy, MA
Background/Purpose: Belimumab, a biologic B-Lymphocyte stimulator (BLyS) inhibitor, was FDA-approved in 2011 for the treatment of active SLE. Initial phase 3 placebo-controlled trials found no…
Abstract Number: 0801 • ACR Convergence 2022
Impact of Diagnosis and Treatment of Tropheryma Whipplei Infection in Patients with Pre-existing Chronic Inflammatory Rheumatic Diseases: Data from the National Tw-IRD Registry
Damien CAILLET PORTILLLO¹, Xavier Puéchal², Yannick Degboe¹, Marie Kostine³, Alexia Michaut⁴, Andre Ramon⁵, Daniel Wendling⁶, Nathalie Costedoat-Chalumeau⁷, Pascal Richette⁸, Hubert Marotte⁹, Justine VIX¹⁰, Jean Jacques Dubost¹¹, Sebastien Ottaviani¹², Gaël Mouterde¹³, Anne Grasland¹⁴, Aline Frazier-Mironer¹⁵, Vincent GERMAIN¹⁶, Fabienne COURY¹⁷, Anne Tournadre¹¹, Martin Soubrier¹⁸, Pauline Brevet¹⁹, Laurent Cavalie²⁰, Laurent Arnaud²¹, Christophe Richez²², Adeline Ruyssen-Witrand²³ and Arnaud Constantin²⁴, ¹Pierre-Paul Riquet University Hospital, Toulouse & Toulouse III University - Paul Sabatier, Rheumatology, Toulouse, France, ²National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ³Pellegrin Hospital, University Hospital of Bordeaux, Rheumatology, Bordeaux, France, ⁴Hospital center, Loire Vendée Ocean, Rheumatology, La Roche-sur-Yon, France, La Roche-sur-Yon, France, ⁵University Hospital of DIJON, Rheumatology, Dijon, France, ⁶CHU, University Teaching Hospital, Besançon, France, ⁷Inserm DR Paris 5, Paris, France, ⁸Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, ⁹INSERM 1059, Saint-Etienne, France, ¹⁰University Hospital of poitiers, Rheumatology, Poitiers, France, Poitiers, France, ¹¹University Hospital of Clermont Ferrand, Rheumatology, Clermont-Ferrand, France, ¹²Hopital Bichat-Claude Bernard, Paris, France, ¹³Lapeyronie Hospital, Montpellier, France, ¹⁴Louis-Mourier Hospital, AP-HP, Colombes, Rheumatology, Colombes, France, ¹⁵APHP Hôpital Lariboisire, Paris, France, ¹⁶Pau Hospital, Rheumatology, Pau, France, Pau, France, ¹⁷Pierre-Bénite Hospital, University Hospital Lyon, Rheumatology, Lyon, France, ¹⁸Gabriel-Montpied Hospital, Clermont-Ferrand, France, ¹⁹University Hospital of Rouen, Rheumatology, Rouen, France., Le Havre, France, ²⁰Purpan Hospital, Federal Institute of Biology (IFB), University Hospital, Toulouse, Biology, Toulouse, France, ²¹Hautepierre Hospital, University Hospital of Strasbourg, Rheumatology, Strasbourg, France, ²²Université de Bordeaux, Bordeaux, France, ²³CHU de Toulouse, Toulouse, France, ²⁴Toulouse University Hospital, Toulouse, France
Background/Purpose: Tropheryma whipplei (Tw) infection is a rare condition, characterized by inflammatory joint symptoms in more than 75% of the cases, which can lead the…
Abstract Number: 1469 • ACR Convergence 2022
Risk Factors for Herpes Zoster Among Patients with Systemic Lupus Erythematosus
Caroline Spitznagel, Fedelis Mutiso, Jim Oates and Diane Kamen, Medical University of South Carolina, Charleston, SC
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a higher prevalence and incidence of herpes zoster (HZ) compared with the general population. Our study was…
Abstract Number: 2059 • ACR Convergence 2022
Association of Hydroxychloroquine with the Incidence of Infectious Disease in Systemic Lupus Erythematosus: Data from the LUNA Registry
Chiharu Hidekawa¹, Ryusuke Yoshimi², Yusuke Saigusa³, Jun Tamura³, Nobuyuki Yajima⁴, Naoki Suzuki⁵, Noriko Kojitani², Yuji Yoshioka⁵, Natsuki Sakurai⁵, Yumiko Sugiyama⁵, Yosuke Kunishita⁶, Daiga Kishimoto⁷, Kana Higashitani⁵, Yuichiro Sato⁵, Takaaki Komiya⁵, Hideto Nagai², Naoki Hamada⁵, Ayaka Maeda⁵, Naomi Tsuchida⁵, Lisa Hirahara², Yutaro Soejima⁵, Kaoru Takase-Minegishi², Yohei Kirino⁵, Ken-ei Sada⁸, Yoshia Miyawaki⁹, Kunihiro Ichinose¹⁰, Shigeru Ohno¹¹, Hiroshi Kajiyama¹², Shuzo Sato¹³, Yasuhiro Shimojima¹⁴, Michio Fujiwara¹⁵ and Hideaki Nakajima⁵, ¹Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama City, Kanagawa Prefecture, Japan, ²Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ³Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan, ⁴Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, ⁵Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan, ⁶Department of Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Kanagawa, Japan, ⁷Center for Rheumatic Diseases, Yokohama City University Medical Center, Kanazawa-ku Yokohamashi, Japan, ⁸Department of Clinical Epidemiology, Kochi Medical School, Kochi University, Okayama, Japan, ⁹Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Yokohama, Japan, ¹⁰Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Yokohama, Japan, ¹¹Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan, ¹²Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Yokohama, Japan, ¹³Department of Rheumatology, Fukushima Medical University School of Medicine, Hikarigaoka, Japan, ¹⁴Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan, ¹⁵Department of Rheumatology, Yokohama Rosai Hospital, Yokohama, Japan
Background/Purpose: Infections are significant causes of mortality in patients with systemic lupus erythematosus (SLE), and their prevention is essential. Although some previous reports have shown…
Abstract Number: L16 • ACR Convergence 2021
Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled Electronic Medical Record Data Repository
Jasvinder Singh¹, Namrata Singh², Alfred Anzalone³, Amy Olex⁴, Jing Sun⁵, Vithal Madhira⁶ and Rena Patel⁷, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Washington, Bellevue, WA, ³University of Nebraska, Omaha, NE, ⁴Virginia Commonwealth University, Richmond, VA, ⁵Johns Hopkins University, Baltimore, MD, ⁶Palila Software, Reno, NV, ⁷Unviersity of Washington, Seattle, WA
Background/Purpose: National U.S. data on breakthrough COVID-19 infection in people with autoimmune or inflammatory rheumatic diseases (AIRD) are limited. Our objective was to assess whether breakthrough COVID-19 infections were increased post-COVID-19-vaccination…
Abstract Number: 0098 • ACR Convergence 2021
Patients with Chronic Inflammatory Rheumatic Diseases Report a Lower Frequency of Infections Than Controls and They Protect Themselves Well Against SARS-CoV-2 Transmission
Iulia Roman, Ioana Andreica, Xenofon Baraliakos, Uta Kiltz and Juergen Braun, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: The SARS-CoV-2 pandemic has affected life in most countries around the world for more than a year now. It is not entirely clear if…
Abstract Number: 0937 • ACR Convergence 2021
Evaluation of the Safety of Vedolizumab in Combination with Other Immunosuppression Biological Therapy in Patients with Inflammatory Bowel Disease
Gino Chesini¹, Elizabeth Parrott¹, Lauren Fox¹, Jenna Beatty¹, Cassandra Effken¹, Na Yu¹, Florence Hosseini-Aslinia¹ and Megan Krause², ¹University of Kansas Medical Center, Kansas City, KS, ²University of Kansas, Kansas City, KS
Background/Purpose: Inflammatory bowel disease (IBD) causes a wide range of symptomology frequently leading to co-management of disease activity between gastroenterologist and rheumatologists. Recently in efforts…
Abstract Number: 1556 • ACR Convergence 2021
Mortality Rate Related to COVID-19 in Rheumatic and Musculoskeletal Diseases (RMDs)
Ines Perez - Sancristobal¹, Dalifer Freites¹, Leticia Lopez Pedraza², Maria Paula Alvarez Hernandez¹, Jose Ignacio Colomer³, Alfredo Madrid - Garcia², Benjamin Fernandez¹, Cristina Vadillo¹, Luis Rodriguez Rodriguez⁴, Arkaitz Mucientes², Leticia Leon - Mateos² and Lydia Abasolo⁵, ¹Hospital Clínico San Carlos, Reumathology, Madrid, Madrid, Spain, ²Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Reumathology, Madrid, Spain, ³Fundación para la Investigación Biomedica, Reumathology, Madrid, Spain, ⁴Hospital Clinico San Carlos, Madrid, Spain, ⁵Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: In patients with rheumatic and musculoskeletal diseases (RMDs) and infected with Covid – 19, a) we want to assess the mortality rate (MR) related…
Abstract Number: 0141 • ACR Convergence 2021
Who Gets Influenza Vaccinations Prior to and After a Diagnosis of RA? Results from the Canadian Early Arthritis Cohort (CATCH)
Viviane Ta¹, Orit Schieir², Marie-France Valois¹, Ines Colmegna³, Carol Hitchon⁴, Louis Bessette⁵, Glen Hazlewood⁶, Carter Thorne⁷, Janet Pope⁸, Gilles Boire⁹, Diane Tin¹⁰, Edward Keystone¹¹, Vivian Bykerk¹², Susan Bartlett¹ and CATCH Investigators¹³, ¹McGill University, Montréal, QC, Canada, ²Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ³The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴University of Manitoba, Winnipeg, MB, Canada, ⁵Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸University of Western Ontario, London, ON, Canada, ⁹Universite de Sherbrooke, Sherbrooke, QC, Canada, ¹⁰The Arthritis Program Research Group, Newmarket, ON, Canada, ¹¹Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ¹²Hospital for Special Surgery, New York, NY, ¹³Canadian Early Arthritis Cohort Investigators, Toronto, ON, Canada
Background/Purpose: Annual influenza vaccination is recommended for adults with RA, but remains low in established RA. We examined influenza vaccination coverage in the year prior…
Abstract Number: 0963 • ACR Convergence 2021
Immunogenicity of COVID-19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Diseases (AIIRDs)
Gordon Lam¹, Andrew Laster², Sarah McCarter², Heather Gladue³, Ahmad Kashif², Erin Siceloff², Victoria Lackey³, Cheryl Robertson³, Ashley Toci² and Leonard Calabrese⁴, ¹Arthritis and Osteoporosis Consultants of the Carolinas, Cornelius, NC, ²Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, ³Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ⁴Cleveland Clinic, Cleveland, OH
Background/Purpose: AIIRD patients may have a blunted immune response to the COVID-19 vaccines, but this is largely uncharacterized as these individuals were not included in…
Abstract Number: 1558 • ACR Convergence 2021
Therapy Based Outcomes in Patients with Multisystem Inflammatory Syndrome in Children: A Single Center Study
Diana Villacis Nunez¹, Kaitlin Jones², Lucie Fan³, Whitney Moore², Aysha Jabbar², Matthew Oster⁴, Preeti Jaggi¹ and Sampath Prahalad⁵, ¹Emory University School of Medicine - Children's Healthcare of Atlanta, Atlanta, GA, ²Children's Healthcare of Atlanta, Atlanta, GA, ³Emory University School of Medicine, Atlanta, GA, ⁴Emory University School of Medicine - Sibley Heart Center/Children's Healthcare of Atlanta, Atlanta, GA, ⁵Emory + Children's Pediatric Institute, Atlanta, GA
Background/Purpose: Management and outcomes of multisystem inflammatory syndrome in children (MIS-C) remain under investigation and vary by institution. This study aimed to describe the outcomes…
Abstract Number: 0203 • ACR Convergence 2021
Chemoprophylaxis in Latent Tuberculosis Associated with Rheumatic Immune-mediated Diseases. Study of 240 Patients from a Single University Hospital
David Martinez-Lopez¹, Javier Rueda-Gotor¹, Joy Osorio-Chávez¹, Carmen Álvarez-Reguera¹, Virginia Portilla², Miguel Ángel gonzalez-Gay³ and Ricardo Blanco⁴, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Tuberculosis (TB) may be increased with biologic therapy (BT). Diagnosis and treatment of latent TB infection (LTBI) is the best strategy to prevent TB.…
Abstract Number: 0965 • ACR Convergence 2021
Anti-TNF Usage in Patients with HIV Infection 2003-2021: Long Term Safety and Followup
Benjamin Naovarat¹, Francis Williams², Gloria Salazar³ and John Reveille⁴, ¹University of Texas McGovern Medical School, Houston, TX, ²Specialists for Health/Wellmed, Shavano Park, TX, ³University of Texas Medical School at Houston/McGovern Medical School, Houston, TX, ⁴Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: There are concerns about using immunosuppressive agents for treatment of rheumatic diseases in patients with HIV infection due to concerns of opportunistic infection. We…
Abstract Number: 1655 • ACR Convergence 2021
Severe Respiratory Infections in Rheumatoid Arthritis Patients with Biologic Therapy: Comparative Study Between Vaccinated and Non Vaccinated Patients
Lucia Cristina Dominguez Casas¹, Paz Rodriguez-Cundin², Trinidad Dierssen³, Miguel Ángel gonzalez-Gay⁴ and Ricardo Blanco⁵, ¹Hospital Universtario San Agustin, Oviedo, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³University of Cantabria, Santander, Spain, ⁴Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁵Hospital Universitario Marqués de Valdecilla, Santadner, Spain
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk of severe infections due to the disease itself, and the immunosuppressive treatment. Vaccination programs are designed…
Abstract Number: 0204 • ACR Convergence 2021
Risk of Hepatitis B Virus Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics After Prophylactic Anti-viral Agents
Soo Min Ahn¹, Jonggi Choi², Byong Duk Ye², Suk-Kyun Yang², Ji Seon Oh³, Yong-Gil Kim², Chang-Keun Lee², Bin Yoo¹, Sang Hyoung Park² and Seokchan Hong², ¹ASAN MEDICAL CENTER, Seoul, South Korea, ²Asan Medical Center, Seoul, Republic of Korea, ³Asan Medical Center, Ulsan, Republic of Korea
Background/Purpose: Prophylactic anti-viral therapy is required in patients with hepatitis B virus (HBV) infection receiving biologics because of the high risk of HBV reactivation. However,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].